Fluvoxamine is a selective serotonin-reuptake inhibitor used to treat obsessive-compulsive disorder. Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor.
- Mechanism
- Curator reviewed · 1 reference
The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. Studies have also demonstrated that fluvoxamine has virtually no affinity for α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, histamine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors, despite having an affinity for binding to σ1 receptors.
- Primary indication
- Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD).Curator reviewed · 3 structured indications
- Formula / weight
- C15H21F3N2O2 · 318.34 g/mol (avg)
- First approval
- Canada, 1999 · United States, 2000
- Brand names
Resolves to
CJOFXWAVKWHTFT-XSFVSMFZSA-NSMILESCOCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)FWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Fluvoxamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account